11 Other financial assets
|
|
Loans associates and joint ventures |
|
Other participating interests |
|
Other receivables |
|
Other |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
Balance at 1 January 2019 |
|
2 |
|
164 |
|
88 |
|
9 |
|
263 |
|
|
|
|
|
|
|
|
|
|
|
Changes: |
|
|
|
|
|
|
|
|
|
|
- Charged to the income statement |
|
- |
|
- |
|
9 |
|
(2) |
|
7 |
- Acquisitions |
|
- |
|
- |
|
- |
|
1 |
|
1 |
- Capital payments |
|
- |
|
23 |
|
- |
|
- |
|
23 |
- Loans granted / prepayments |
|
4 |
|
- |
|
9 |
|
- |
|
13 |
- Repayments |
|
(2) |
|
- |
|
(5) |
|
- |
|
(7) |
- Exchange differences |
|
- |
|
- |
|
1 |
|
- |
|
1 |
- Transfers |
|
(1) |
|
(15) |
|
3 |
|
- |
|
(13) |
- Changes in fair value |
|
- |
|
(21) |
|
- |
|
- |
|
(21) |
- Other |
|
- |
|
(1) |
|
- |
|
(1) |
|
(2) |
Balance at 31 December 2019 |
|
3 |
|
150 |
|
105 |
|
7 |
|
265 |
|
|
|
|
|
|
|
|
|
|
|
Changes: |
|
|
|
|
|
|
|
|
|
|
- Charged to the income statement |
|
- |
|
- |
|
- |
|
(2) |
|
(2) |
- Acquisitions |
|
- |
|
- |
|
- |
|
4 |
|
4 |
- Disposals |
|
- |
|
(47) |
|
- |
|
- |
|
(47) |
- Capital payments |
|
- |
|
11 |
|
- |
|
- |
|
11 |
- Loans granted / prepayments |
|
1 |
|
- |
|
8 |
|
- |
|
9 |
- Repayments |
|
- |
|
- |
|
(5) |
|
4 |
|
(1) |
- Exchange differences |
|
- |
|
- |
|
(10) |
|
- |
|
(10) |
- Transfers |
|
- |
|
- |
|
(7) |
|
(4) |
|
(11) |
- Changes in fair value |
|
- |
|
106 |
|
- |
|
- |
|
106 |
- Other |
|
- |
|
(1) |
|
(6) |
|
- |
|
(7) |
Balance at 31 December 2020 |
|
4 |
|
219 |
|
85 |
|
9 |
|
317 |
‘Disposals’ includes the divestment of our other participating interest in probiotic company UAS Laboratories, Inc.
‘Changes in fair value’ consists mainly of the value increase of our minority share in Amyris, Inc. (€78 million) and of our share in UAS Laboratories, Inc. prior to divestment (€38 million).